Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 69.4%, EPS grew 10.4%, free cash flow grew 288.1% and total debt was flat, each against the same quarter a year earlier.
Follow TARS
Tarsus Pharmaceuticals, Inc. (TARS) EV/Sales
As of 16 October 2026, Tarsus Pharmaceuticals, Inc. (TARS) trades at a EV/Sales of 4.3×. Over the past ten years it has ranged from 0.0× (December 2021) to 34.8× (February 2024); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.8× | (33.07%) |
| FY2024 | 10.2× | (29.21%) |
| FY2023 | 14.4× | 138.93% |
| FY2022 | 6.0× | 17.86% |
| FY2021 | 5.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.9× | (22.97%) |
| Mar 2026 | 5.0× | (26.03%) |
| Dec 2025 | 6.8× | 13.27% |
| Sep 2025 | 6.0× | 26.37% |
| 16 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| VKTX Viking Therapeutics, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. | 4.3× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.4× |
| TNGX Tango Therapeutics, Inc. compare | 36.7× |
| XENE Xenon Pharmaceuticals Inc. compare | 144× |
| RLAY Relay Therapeutics, Inc. compare | 217× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)